

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/541,708		ATTY. DOCKET NO.: A0848.70010US00	
				FILING DATE: July 8, 2005		CONFIRMATION NO.: 6032	
				APPLICANT: Karen Silence			
				GROUP ART UNIT: 1644		EXAMINER: Sziperka, Michael Edward	
Sheet	1	of	1				

U.S. PATENT DOCUMENTS

Examiner's Initials *	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A8	6,419,934		Tobinick	07-16-2002

FOREIGN PATENT DOCUMENTS

Examiner's Initials *	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	B6	EP	1 002 861	A1	Unilever PLC	05-24-2000	
	B7	EP	0 368 684	B1	Medical Research Council	03-09-1994	
	B8	WO	93/11161	A1	Enzon, Inc.	06-10-1993	
	B9	WO	94/13806	A1	The Dow Chemical Company	06-23-1994	
	B10	WO	99/09055	A2	Innogenetics N.V.	02-25-1999	
	B11	WO	99/23221	A2	Unilever PLC; Unilever N.V.	05-14-1999	
	B12	WO	2004/003019	A2	Domantis Limited	01-08-2004	
	B13	WO	90/10707	A1	Jonker	09-20-1990	
	B14	WO	94/04678	A1	Casterman	03-03-1994	
	B15	WO	94/25591	A1	Unilever N.V.; Unilever PLC	11-10-1994	
	B16	WO	97/38102	A1	Unilever PLC; Unilever N.V.	10-16-1997	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials *	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C13	ILL, C.R. et al., "Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions," <i>Protein Engineering</i> 1997; 10(8):949-957	
	C14	TANHA, J. et al., "Selection by phage display of llama conventional V _H fragments with heavy chain antibody V _H H properties," <i>Journal of Immunological Methods</i> 2002; 263:97-109	
	C15	VALLE, E. et al., <i>Expert Opin. Pharmacother.</i> 2001; 2(6):1015-1025	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE -- No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]